News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA before special items falls 1.3 percent to € 4.41 billion
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
New solvent-free micronization technology expanded at the Darmstadt site in Germany
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Subscribe To Our Newsletter & Stay Updated
